| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 148, 1531-1541, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
RM Przygodzki, SD Finkelstein, JC Langer, PA Swalsky, N Fishback, A Bakker, DG Guinee, M Koss and WD Travis
Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA.
Neuroendocrine tumors of lung, including typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC) constitute a spectrum of malignancies in which the pathologist at times has difficulty in discerning tumor subtype and aggressiveness in a reproducible fashion. Therefore, 59 primary neuroendocrine lung tumors including 10 TCs, 26 ACs, 15 LCNECs, and 8 SCLCs were selected from cases collected from 1976 to 1988 and immunostained for p53 protein. All of these tumors were also genotyped for specific point mutational damage affecting p53 (exons 5, 7, and 8; with ACs additionally sequenced for p53 exon 6); 13 tumors for K-ras-2 (exon 1); and 31 tumors for c-raf-1 (exon 15) growth- regulatory genes. Genotyping was performed on topographically selected, minute tumor samples removed from unstained formalin-fixed, paraffin- embedded tissue sections (topographic genotyping) using polymerase chain reaction and direct sequencing. The distribution of p53 immunohistochemical staining had four patterns: negative in TCs, one- half of ACs, 3 of 15 LCNECs, and 1 of 8 SCLCs; less than 10% but more than five tumor cells per 10 high power fields (focal) in a subset (7 of 26) of aggressive ACs; 10 to 49% of tumor cells (patchy) in a subset (6 of 26) of ACs with a higher grade of aggressiveness; and 50 to 100% of tumor cells (diffuse), exclusively seen in LCNECs (12 of 15) and SCLCs (7 of 8). Three patterns of immunohistochemical staining intensity of p53 protein were seen: negative, weak or mild, and moderate to marked. SCLCs and LCNECs accounted for cases of moderate to marked staining and were the only ones to have mutations in p53 exons 5, 7, or 8. No mutations were found in AC and TC, showing absent to weak staining and no staining, respectively. The difference in distribution and staining intensities between LCNEC and SCLC compared with AC and TC was statistically significant (P < 0.001). Patients having AC with patchy p53 immunostaining usually had survival limited to 3 years, whereas those having AC with focal p53 immunostaining subsequently developed metastatic or recurrence of AC disease (P < 0.05). The absence of point mutations in cases with patchy or focal immunostaining suggests increased expression of wild-type p53 tumor suppressor protein likely in response to growth deregulation in a more aggressive subtype of AC. A novel hypothesis is presented in regard to these findings. K-ras-2 and c-raf-1 gene sequence analysis showed no evidence of point mutational change in any of the tumors studied. The TC and AC categories are therefore genetically distinct from the higher grade neuroendocrine SCLC and LCNEC. Immunohistochemistry for p53 on AC lung tumors may be helpful to delineate cases at higher risk for aggressive behavior. Additionally, although LCNEC is categorized as a non-small-cell carcinoma, it is more akin genetically and immunohistochemically to SCLC.
This article has been cited by other articles:
 |
|
 |
|
  A. Iyoda, K. Hiroshima, Y. Nakatani, and T. Fujisawa Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al. Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6748 - 6757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, Y. Moriya, Y. Takiguchi, Y. Sekine, K. Shibuya, T. Iizasa, H. Kimura, Y. Nakatani, and T. Fujisawa Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma Ann. Thorac. Surg., November 1, 2006; 82(5): 1802 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ab' Saber, L. M. Massoni Neto, C. P. Bianchi, B. B. Ctenas, E. R. Parra, E. M. Eher, J. C. Pereira, T. Takagaki, N. H. Yamaguchi, and V. L. Capelozzi Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas Ann. Thorac. Surg., June 1, 2004; 77(6): 1883 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, Y. Moriya, T. Mizobuchi, M. Otsuji, Y. Sekine, K. Shibuya, T. Iizasa, Y. Saitoh, and T. Fujisawa Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity Ann. Thorac. Surg., June 1, 2004; 77(6): 1891 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Casali, A. Stefani, G. Rossi, M. Migaldi, S. Bettelli, A. Parise, and U. Morandi The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung Ann. Thorac. Surg., January 1, 2004; 77(1): 247 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hage, A. B. de la Riviere, C.A. Seldenrijk, and J.M. M. van den Bosch Update in Pulmonary Carcinoid Tumors: A Review Article Ann. Surg. Oncol., July 1, 2003; 10(6): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, M. Baba, Y. Saitoh, H. Ohwada, and T. Fujisawa Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors Ann. Thorac. Surg., April 1, 2002; 73(4): 1049 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Finkelstein, R. Dhir, M. Rabinovitz, M. Bischeglia, P. A. Swalsky, P. DeFlavia, J. Woods, A. Bakker, and M. Becich Cold-Temperature Plastic Resin Embedding of Liver for DNA- and RNA-Based Genotyping J. Mol. Diagn., November 1, 1999; 1(1): 17 - 22. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. D. Finkelstein, T. Hasegawa, T. Colby, and S. A. Yousem 11q13 Allelic Imbalance Discriminates Pulmonary Carcinoids from Tumorlets : A Microdissection-Based Genotyping Approach Useful in ClinicalPractice Am. J. Pathol., August 1, 1999; 155(2): 633 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Walch, H. F. Zitzelsberger, M. M. Aubele, A. E. Mattis, M. Bauchinger, S. Candidus, H. W. Prauer, M. Werner, and H. Hofler Typical and Atypical Carcinoid Tumors of the Lung Are Characterized by 11q Deletions as Detected by Comparative Genomic Hybridization Am. J. Pathol., October 1, 1998; 153(4): 1089 - 1098. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
